Drs James Wilson and Maria Limberis from the Gene Therapy Program collaborated on this study and discovered that this approach could offer protection against multiple strains of influenza.
GTP Director Dr James M Wilson is among the four finalists named for this prestigious award.
Jean Bennett and Katherine A. High, Brian Kaspar and James M. Wilson named as contenders for inaugural award.
Inconsistency in the molecular makeup of vectors is a key concern in scaling up gene therapy production for patients.
Gene Therapies Will Target Rare Immune, Lymph Node, and Growth Disorders.